Figure 2.

Metastatic triple negative breast cancer cells without BRCA1 (BReast CAncer 1 gene) mutation in response to PARPi. MDA-MB-231 and MDA-MB-468 were treated with Poly (ADP-ribose) polymerase inhibitors (PARPi) from 0.001 to 200 µM for 7 days, and then the cell viabilities and IC₅₀ of the indicated PARPi were determined as described in the Methods Section. (A) Inhibition curves in the cells under the indicated PARPi treatments. Points: mean of three and bars represent standard errors. (B,C) The bars indicate mean of the half maximal inhibitory concentration (IC₅₀) of the indicated PARPi for MDA-MB-231 (B) and MDA-MB-468 (C) cells. The IC₅₀ values were estimated by using the semi logarithm-transformed dose-response data with a Linear Regression model. The number presented on top of the bars indicate the mean IC₅₀ for the indicated PARPi.